 Thalidomide
"Thalidomide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
| Descriptor ID |
D013792
|
| MeSH Number(s) |
D02.241.223.805.810.800 D03.383.621.808.800 D03.633.100.513.750.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thalidomide".
Below are MeSH descriptors whose meaning is more specific than "Thalidomide".
This graph shows the total number of publications written about "Thalidomide" by people in this website by year, and whether "Thalidomide" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 | | 1999 | 1 | 0 | 1 | | 2000 | 0 | 1 | 1 | | 2002 | 1 | 0 | 1 | | 2006 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 | | 2010 | 0 | 2 | 2 | | 2011 | 0 | 1 | 1 | | 2012 | 1 | 1 | 2 | | 2013 | 4 | 1 | 5 | | 2014 | 1 | 0 | 1 | | 2015 | 1 | 2 | 3 | | 2017 | 2 | 1 | 3 | | 2018 | 1 | 2 | 3 | | 2019 | 1 | 1 | 2 | | 2020 | 0 | 2 | 2 | | 2024 | 1 | 1 | 2 | | 2025 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Thalidomide" by people in Profiles.
-
Moreno DF, Oriol A, de la Rubia J, Hernández MT, Iñigo MB, Palomera L, de Arriba F, González Y, Teruel AI, Pardo JL, López de la Guía A, Sampol A, Ríos-Tamayo R, Sureda A, Gutiérrez NC, Calasanz MJ, Ramos MLM, Mateos MV, San Miguel J, Lahuerta JJ, Bladé J, Rosiñol L. Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials. Clin Lymphoma Myeloma Leuk. 2025 Jul; 25(7):494-504.
-
Davis LN, Walker ZJ, Reiman LT, Parzych SE, Stevens BM, Jordan CT, Forsberg PA, Sherbenou DW. MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance. Clin Cancer Res. 2024 Jul 15; 30(14):3023-3035.
-
Kubicki T, Jamroziak K, Robak P, Czyz J, Tyczynska A, Druzd-Sitek A, Giannopoulos K, Wróbel T, Nowicki A, Szczepaniak T, Lojko-Dankowska A, Matuszak M, Gil L, Pula B, Szukalski L, Konska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Kruk-Kwapisz D, Derman BA, Major A, Jakubowiak AJ, Dytfeld D. Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone. Pol Arch Intern Med. 2024 05 28; 134(5).
-
Mark T, Falkenstein A, Kish J. Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma. Future Oncol. 2022 Feb; 18(5):553-564.
-
Bradbury CA, Craig Z, Cook G, Pawlyn C, Cairns DA, Hockaday A, Paterson A, Jenner MW, Jones JR, Drayson MT, Owen RG, Kaiser MF, Gregory WM, Davies FE, Child JA, Morgan GJ, Jackson GH. Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. Blood. 2020 08 27; 136(9):1091-1104.
-
Jackson GH, Pawlyn C, Cairns DA, Striha A, Collett C, Waterhouse A, Jones JR, Wilson J, Taylor C, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Jenner MW, Cook G, Russell NH, Drayson MT, Kaiser MF, Owen RG, Gregory WM, Davies FE, Morgan GJ. Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. Br J Haematol. 2021 03; 192(5):853-868.
-
Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019 Sep; 6(9):e459-e469.
-
Mark TM, Forsberg PA, Rossi AC, Pearse RN, Pekle KA, Perry A, Boyer A, Tegnestam L, Jayabalan D, Coleman M, Niesvizky R. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma. Blood Adv. 2019 02 26; 3(4):603-611.
-
Jones JR, Weinhold N, Ashby C, Walker BA, Wardell C, Pawlyn C, Rasche L, Melchor L, Cairns DA, Gregory WM, Johnson D, Begum DB, Ellis S, Sherborne AL, Cook G, Kaiser MF, Drayson MT, Owen RG, Jackson GH, Davies FE, Greaves M, Morgan GJ. Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica. 2019 07; 104(7):1440-1450.
-
Guttman-Yassky E, Hanifin JM, Boguniewicz M, Wollenberg A, Bissonnette R, Purohit V, Kilty I, Tallman AM, Zielinski MA. The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition. Exp Dermatol. 2019 01; 28(1):3-10.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|